Howard Lee


Fixing paper assignments

  1. Please select all papers that belong to the same person.
  2. Indicate below which author they should be assigned to.
Provide a valid ORCID iD here. This will be used to match future papers to this author.
Provide the name of the school or the university where the author has received or will receive their highest degree (e.g., Ph.D. institution for researchers, or current affiliation for students). This will be used to form the new author page ID, if needed.

TODO: "submit" and "cancel" buttons here


2024

pdf bib
CReSE: Benchmark Data and Automatic Evaluation Framework for Recommending Eligibility Criteria from Clinical Trial Information
Siun Kim | Jung-Hyun Won | David Lee | Renqian Luo | Lijun Wu | Tao Qin | Howard Lee
Findings of the Association for Computational Linguistics: EACL 2024

Eligibility criteria (EC) refer to a set of conditions an individual must meet to participate in a clinical trial, defining the study population and minimizing potential risks to patients. Previous research in clinical trial design has been primarily focused on searching for similar trials and generating EC within manual instructions, employing similarity-based performance metrics, which may not fully reflect human judgment. In this study, we propose a novel task of recommending EC based on clinical trial information, including trial titles, and introduce an automatic evaluation framework to assess the clinical validity of the EC recommendation model. Our new approach, known as CReSE (Contrastive learning and Rephrasing-based and Clinical Relevance-preserving Sentence Embedding), represents EC through contrastive learning and rephrasing via large language models (LLMs). The CReSE model outperforms existing language models pre-trained on the biomedical domain in EC clustering. Additionally, we have curated a benchmark dataset comprising 3.2M high-quality EC-title pairs extracted from 270K clinical trials available on ClinicalTrials.gov. The EC recommendation models achieve commendable performance metrics, with 49.0% precision@1 and 44.2% MAP@5 on our evaluation framework. We expect that our evaluation framework built on the CReSE model will contribute significantly to the development and assessment of the EC recommendation models in terms of clinical validity.